ndothelin-1 (ET-1) is a vasoactive peptide that causes vasoconstriction and vasodilation by binding to ET A receptors on vascular smooth muscle cells and ET B receptors on endothelial cells, respectively. [1] [2] [3] In the kidney, ET-1 is synthesized from a variety of cells such as vascular endothelium, mesangial cells, tubular epithelial cells, and medullary interstitium. 4 -10 The primary receptor subtype on renal tubular epithelial cells is the ET B receptor. 3 Studies have demonstrated that ET-1 stimulates sodium and water excretion through ET B receptor activation. 11 Consistent with a pronatriuretic function, our laboratory has shown that blocking ET B receptors causes salt-dependent hypertension along with elevated plasma ET-1 levels. 12, 13 The latter effect is thought to be attributable to reduced clearance of ET-1 in the absence of ET B receptor availability.
The role of cytochrome P450 (CYP450) hydroxylase metabolites in the maintenance of arterial pressure is complex because of their contrasting hypertensive and antihypertensive properties. 14 Clofibrate, a peroxisome proliferator activated receptor-␣ (PPAR-␣) agonist, has been shown to reduce arterial pressure in Dahl salt-sensitive rats on high salt diet by inducing the genes that code for CYP4504A (CYP4A) enzymes in the renal cortex. 15, 16 CYP4A is the enzyme responsible for the synthesis of 20-HETE. Interestingly, 20-HETE has actions to reduce sodium transport and, like ET B receptor activation, has been implicated in saltdependent hypertension. [17] [18] [19] [20] [21] Previous studies have provided evidence that 20-HETE contributes to ET-1-mediated natriuretic responses. 22 Blockade of CYP4A and 20-HETE prevented the increase in urinary sodium excretion produced by ET-1. 23 Similarly, inhibition of 20-HETE formation in isolated proximal tubules prevented the blockade of ion transport produced by ET-1, indicating that 20-HETE acts as a second messenger of ET-1 in the proximal tubule. 23 Because the ET-1-mediated diuretic and natriuretic effects are through ET B activation, it is reasonable to presume that ET-1 stimulates 20-HETE formation through ET B receptors. The purpose of the present study was to determine the influence of PPAR-␣ activation and upregulation of CYP4A in the salt-sensitive hypertension produced by chronic ET B receptor blockade.
Methods

Telemetry Blood Pressure Measurements
Telemetry transmitters (Data Sciences International) were implanted according to manufacturer specifications into male and female Sprague-Dawley rats (175 to 200 g; Harlan Laboratories; Indianapolis, Ind) as described previously. 12 In brief, a midline incision was used to expose the abdominal aorta, which was momentarily occluded to allow implantation of the transmitter catheter that was secured in place with tissue glue. The transmitter body was sutured to the abdominal wall while closing the incision. The skin was closed with staples that were removed 7 to 10 days later, after the incision was healed. Rats were returned to their individual cages and allowed to recover for Ն1 week before being used in experiments. Cages were placed on top of the telemetry receivers, and arterial pressure and heart rate measurements were recorded continuously, except on days when rats were placed in metabolic cages.
Protocol
Rats were given free access to chow that contained either normal (0.8%) or high (8%) NaCl for 10 days. After 3 days of baseline, rats were placed in metabolic cages for 24-hour urine collection. Then rats were divided into 3 groups: (1) clofibrate, a PPAR-␣ agonist, at 80 mg per day in the drinking water; (2) A-192621, a selective ET B receptor antagonist, at 10 mg/kg per day in the food; and (3) clofibrate and A-192621. The doses of A-192621 and clofibrate were chosen from previously published studies. 12, 13, 16 Rats were again placed in metabolic cages on the seventh day of drug treatment. After 7 days of treatment with A-192621 or clofibrate, rats were anesthetized with pentobarbital (65 mg/kg IP), and kidneys were removed and separated into the renal cortex and renal medulla before being frozen in liquid nitrogen.
Immunoblot Analysis of CYP4A Protein
Kidney cortex and medulla were homogenized in buffer containing 100 mmol/L Tris-HCl and 1.15% KCl, pH 7.4. Homogenates were centrifuged at 10 000g for 30 minutes. Protein was separated by electrophoresis on 10% stacking Tris-glycine gels before being were transferred electrophoretically to nitrocellulose membranes. The primary antibodies used were goat anti-rat CYP4A1 polyclonal antibody (1:2000; BD Gentest) and rabbit anti-rat CYP2C23 polyclonal antibody (1:5000; Dr Capedevila, Vanderbilt University, Nashville, Tenn). Blots were then washed in a PBS-0.1% Tween 20 solution and incubated with their respective secondary antibodies for 1 hour at room temperature and washed again. The secondary antibodies for CYP4A1 and CYP2C23 were donkey antigoat IgGhorseradish peroxidase (HRP; 1:40 000) and goat anti-rabbit IgG-HRP (1:100 000), respectively. Detection was accomplished with the use of enhanced chemiluminescence (ECL; Amersham Corp), and blots were exposed to x-ray film (Hyperfilm-ECL; Amersham Corp). CYP4A1 band intensity was measured densitometrically, and the values were normalized to expression of ␤-actin.
Statistical Analysis
ANOVA for repeated measures, combined with post hoc tests, was used for statistical evaluation of mean values for every 12-hour telemetry measurement (SuperANOVA; Abacus Concepts Inc.). ANOVA combined with Newman-Keuls multiple comparison tests was used for statistical evaluation of mean values for 24-hour arterial pressure and heart rate telemetry measurements and CYP4A protein expression (Graph Pad Prism 4; Graph Pad Software, Inc.). Values are reported as meansϮSE with PϽ0.05 being considered significant.
Results
On a normal-salt diet, all groups of rats had a similar baseline arterial pressure averaging 106Ϯ2 mm Hg during the final 24 hours of blood pressure measurement before drug treatment ( Figure 1 ). Clofibrate treatment had no effect on mean arterial pressure (MAP). Blockade of ET B receptors with A-192621 (10 mg/kg per day) significantly increased MAP by 15Ϯ3 mm Hg on the final day compared with baseline (PϽ0.05) and was not statistically different from male rats treated with A-192621 plus clofibrate; MAP increased by 7Ϯ2 mm Hg in the latter group. There were no significant differences in heart rate between the groups of rats on a normal-salt diet (Table) .
As shown in Figure 2 , placing male rats on a high-salt diet produced a small but significant increase in basal arterial pressures compared with male rats on a normal-salt diet; 24 hour MAP was 118Ϯ2 mm Hg by the third day on the high-salt diet. Treatment with A-192621 significantly increased MAP in male rats compared with baseline and compared with rats treated with clofibrate alone; the change in 24-hour MAP was 34Ϯ3 versus Ϫ8Ϯ1 mm Hg in A-192621 versus clofibrate-treated rats, respectively (PϽ0.05). The decrease in MAP produced by clofibrate treatment alone in rats on a high-salt diet was small but significant compared with baseline. Administration of clofibrate significantly inhibited the increase in MAP produced by A-192621; the change in 24-hour MAP was 19Ϯ4 mm Hg (PϽ0.05 versus A-192621 alone). There were no significant differences in heart rate among groups of rats on a high-salt diet (Table) .
Metabolic Cage and Telemetry Data of Rats Treated
Similar to male rats, blockade of ET B receptors in female rats on a high-salt diet significantly increased in MAP ( Figure  3 ). The change in MAP from baseline was 29Ϯ4 mm Hg in female rats treated with A-192621 alone; that was significantly reduced in rats given A-192621 plus clofibrate. The change in MAP was 15Ϯ2 mm Hg in the latter group. Clofibrate alone did not have a significant effect on MAP in female rats on a high-salt diet. The different drug treatments had no effect on heart rate in female rats (Table) .
Before treatment with A-192621 or clofibrate, 24-hour food and water intake, as well as urine volume and sodium excretion, was not different among groups of rats on normalor high-salt diets (data not shown). Similarly, at the end of the drug treatment period, food and water intake was not different among groups of rats on the same diet; nor were there any differences in urine volume and sodium excretion (Table) .
In male rats on a high-salt diet, there was a tendency for clofibrate treatment to increase renal cortical CYP4A protein expression, but this did not reach statistical significance compared with untreated control rats ( Figure 4A ). Chronic A-192621 treatment significantly decreased renal cortical CYP4A protein expression compared with untreated control rats. Administration of clofibrate significantly increased cortical CYP4A protein expression in male rats on a high-salt diet treated with A-192621. Clofibrate treatment significantly increased CYP4A expression in the renal medulla of rats on high salt alone and rats fed a high-salt diet during chronic ET B receptor blockade ( Figure 4B) . A-192621 treatment alone had no effect on renal medullary CYP4A expression. Neither clofibrate nor A-192621 treatments had any effect on CYP2C23 protein expression in the renal cortex or renal medulla ( Figure 5A and 5B).
Discussion
Recently, studies from our laboratory provided evidence that blocking ET B receptors causes a significant increase in arterial pressure in rats on a normal-salt diet and that this increase in arterial pressure is augmented by a high-salt diet. 12, 13 Therefore, the lack of ET B receptor function causes a salt-dependent hypertension. Similar to ET B -deficient rats, 24, 25 the hypertension can be attenuated with an ET A receptor antagonist. 12, 26 These results indicate that the elevation in arterial pressure is attributable to the blockade of the antihypertensive effects of ET B receptors and to the stimulation of the prohypertensive effects of ET A receptors. The important findings from the present study indicate that blocking ET B receptors in rats on a high-salt diet decreased renal cortical CYP4A protein expression and that the administration of clofibrate, a PPAR-␣ agonist, reversed the decrease in renal CYP4A expression and the increase in arterial pressure produced by chronic ET B receptor blockade.
The current study examined whether the salt-dependent hypertension produced by chronic ET B receptor blockade is related to a reduction in the protein levels of CYP4A enzymes. Previous studies have demonstrated that the induction of the renal CYP4A enzyme attenuates the development of hypertension in Dahl salt-sensitive rats 15, 16, 21 and that the inhibition of 20-HETE, a metabolite of CYP4A, causes hypertension. 19, 27 Additionally, the antihypertensive actions of 20-HETE can be attributed to inhibition of sodium transport by the proximal tubule and thick ascending limb of the loop of Henle. 14, 20, 22 Blockade of ion transport in freshly isolated proximal tubules by ET-1 is attenuated by inhibiting 20-HETE synthesis. 22 The significance of these findings and the current study provide support for the hypothesis that ET-1 increases CYP4A expression through the activation of ET B receptors, which would result in an inhibition of sodium transport in the cortical region of the kidney via 20-HETE.
PPAR-␣ receptors are highly expressed in the proximal tubules, but their functional role remains unclear. 28, 29 Roman et al demonstrated that PPAR-␣ activation increases CYP4A, leading to enhanced 20-HETE synthesis and to normalizing arterial pressure in Dahl salt-sensitive rats. 15, 16, 21 Our findings are somewhat similar because A-192621 caused a significant increase in MAP in rats fed a high-salt diet, and the administration of clofibrate inhibited this response. In contrast, clofibrate had no effect on arterial pressure in rats treated with A-192621 on a normal-salt diet.
All studies investigating the effects of chronic blockade of ET B receptors have been conducted in male rats. 12, 13 This is the first study to our knowledge that has examined chronic ET B inhibition in female rats. A-192621 treatment in female rats on a high-salt diet increased MAP, which was very similar to the male rats on a high-salt diet. Conversely, female ET B -deficient sl/sl rats on a high-sodium diet have significantly higher arterial pressures compared with their male counterparts. 24 This may be attributed to female ET B -deficient rats not having functional ET B receptors in their kidneys for their entire period of development. Clofibrate treatment significantly lowered MAP in A-192621-treated female rats on high-salt diet much to the same degree as male rats. Similarly, clofibrate has been shown to reduce arterial pressure in female Dahl S rats by inducing CYP4A protein expression in the renal cortex. 15 Previous studies have demonstrated that androgens regulate expression of CYP450 enzymes, and androgens alone upregulate CYP450 enzymes. 30, 31 In the present study, clofibrate was able to significantly increase CYP4A protein expression in male rats on a high-salt diet during chronic ET B receptor blockade.
We cannot exclude the possible role of increased renal production of epoxyeicosatrienoic acids in mediating the decrease in arterial blood pressure in male rats on a high-salt diet during chronic ET B blockade. PPAR-␣ activation has been shown to induce renal CYP2C23 activity under pathological and nonpathological conditions. 32, 33 Contrary to the effects of A-192621 treatment on CYP4A expression in rats on high salt, chronic ET B blockade did not change CYP2C23 protein expression. Furthermore, clofibrate administration did not influence CYP2C23 expression in A-192621-treated rats on a high-salt diet. These data suggest that ET B receptor activation does not regulate CYP2C23 enzyme expression in the kidney.
Our finding that chronic ET B blockade did not change CYP4A protein expression in the renal medulla is somewhat unexpected, given the observed changes in cortical expression. There is an abundance of ET B receptors located in the renal medulla that promote sodium and water excretion by increasing medullary blood flow or through direct inhibition of tubular transport. 34, 35 Other studies have observed that ET increases production of prostaglandin E 2 (PGE 2 ) in several cell types within the renal medulla. 36 -38 Furthermore, blockade of PGE 2 leads to a potentiation of ET-1-induced vasoconstriction. 36, 39 Therefore, it would appear as though the primary mechanisms for inhibiting transport via ET B receptors in the medulla are through the release of NO and PGE 2 production and may not be dependent on CYP450 metabolites. Further studies will need to clarify this possibility.
In conclusion, the downregulation of CYP4A protein expression in the cortex during chronic ET B blockade may contribute to salt-dependent hypertension because the CYP4A metabolites have been shown to inhibit sodium transport from the lumen of the proximal tubule, the thick ascending limb, and the collecting duct. 22, 40, 41 An important finding from the current study was that inhibition of ET B receptors significantly decreased CYP4A protein expression. These data suggest that ET-1 and ET B receptors in rats on a high-salt diet function to maintain CYP4A enzyme expression and possibly 20-HETE production. These results indicate that chronic treatment with a PPAR-␣ agonist can blunt the increase in arterial pressure produced by chronic ET B receptor blockade, and ET-1, via the ET B receptor, regulates CYP4A protein expression in the renal cortex. The specific mechanisms linking ET-1 and CYP4A have yet to be elucidated.
Perspectives
These findings suggest that CYP4A may play an important role in the development of hypertension during chronic ET B receptor blockade. When chronically blocking ET B receptors in rats on high-salt diet, CYP4A protein expression in the renal cortex was significantly decreased. This led us to speculate that the decrease in CYP4A expression translates to a decrease in 20-HETE synthesis that would increase tubular sodium reabsorption. Therefore, this study also provides further support for the hypothesis that 20-HETE may act as a second messenger of ET-1 to inhibit sodium transport in the cortical region of the kidney.
Escalante et al demonstrated that ET-1 and 20-HETE block ion transport in freshly isolated proximal tubules. 22 Coadministration of 12,12-dibromododecenoic acid, an inhibitor of 20-HETE reduction, attenuated this effect. In addition, ET-1 stimulated the release of 20-HETE from isolated proximal tubules. 22 These results provide the first line of evidence that 20-HETE may play a significant role in the natriuretic actions of ET-1. In the thick ascending limb, Plato et al provided evidence that ET-1 decreases sodium transport through the activation of ET B receptors, which may contribute to the natriuretic effects of ET-1 observed in vivo. 35 Work from Roman's laboratory has shown that 20-HETE production is decreased in the thick ascending limb of Dahl salt-sensitive rats and that the elevated Cl Ϫ flux can be attenuated by adding 20-HETE. 42, 43 Furthermore, the administration of clofibrate increased CYP4A activity and 20-HETE synthesis and improved pressure natriuresis in Dahl salt-sensitive rats. 15 Together with the current study, these data provide a growing line of evidence that an interaction between ET-1 and a CYP4A metabolite, most likely 20-HETE, functions to reduce renal tubular sodium reabsorption in response to elevations in dietary salt intake.
